[go: up one dir, main page]

GB201900732D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201900732D0
GB201900732D0 GBGB1900732.7A GB201900732A GB201900732D0 GB 201900732 D0 GB201900732 D0 GB 201900732D0 GB 201900732 A GB201900732 A GB 201900732A GB 201900732 D0 GB201900732 D0 GB 201900732D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1900732.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Oxford University Innovation Ltd
Original Assignee
UCB Biopharma SRL
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL, Oxford University Innovation Ltd filed Critical UCB Biopharma SRL
Priority to GBGB1900732.7A priority Critical patent/GB201900732D0/en
Publication of GB201900732D0 publication Critical patent/GB201900732D0/en
Priority to PCT/GB2020/050103 priority patent/WO2020148554A1/en
Priority to EP20701856.5A priority patent/EP3911414A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1900732.7A 2019-01-18 2019-01-18 Antibodies Ceased GB201900732D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1900732.7A GB201900732D0 (en) 2019-01-18 2019-01-18 Antibodies
PCT/GB2020/050103 WO2020148554A1 (en) 2019-01-18 2020-01-17 Antibodies to ebola virus glycoprotein
EP20701856.5A EP3911414A1 (en) 2019-01-18 2020-01-17 Antibodies to ebola virus glycoprotein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1900732.7A GB201900732D0 (en) 2019-01-18 2019-01-18 Antibodies

Publications (1)

Publication Number Publication Date
GB201900732D0 true GB201900732D0 (en) 2019-03-06

Family

ID=65528322

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1900732.7A Ceased GB201900732D0 (en) 2019-01-18 2019-01-18 Antibodies

Country Status (3)

Country Link
EP (1) EP3911414A1 (en)
GB (1) GB201900732D0 (en)
WO (1) WO2020148554A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250188154A1 (en) * 2020-09-15 2025-06-12 Duke University Coronavirus antibodies and uses thereof
WO2022087458A1 (en) * 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
JP2024522069A (en) 2021-05-19 2024-06-11 アシャ バイオセラピューティクス，インク． IL-21 Polypeptides and Targeting Constructs

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68927933T2 (en) 1988-09-02 1997-08-14 Dyax Corp PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ES2284161T3 (en) 1990-01-12 2007-11-01 Amgen Fremont Inc. GENERATION OF XENOGENIC ANTIBODIES.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (en) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fab fragments of modified antibodies
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
BRPI0615026A8 (en) 2005-08-19 2018-03-06 Abbott Lab double variable domain immunoglobulin and its uses
ES2622460T3 (en) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusions of antibodies with double specificity
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US20170121391A1 (en) * 2015-07-07 2017-05-04 Wisconsin Alumni Research Foundation (Warf) Potent glycoprotein antibody as a therapeutic against ebola virus
US11135280B2 (en) * 2016-03-28 2021-10-05 Integrated Biotherapeutics, Inc. Modified ebolavirus glycoproteins comprising mutations in the head and base domains that increase antibody cross-reactivity
CN110087677B (en) * 2016-10-11 2023-12-08 生物综合治疗有限公司 Broadly neutralizing antibodies targeting the inner fusion loop of ebola virus glycoprotein

Also Published As

Publication number Publication date
WO2020148554A1 (en) 2020-07-23
EP3911414A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
IL280780A (en) Anti-tigit antibodies
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Anti-tigit antibodies
IL280013B1 (en) Anti-il36r antibodies
SG11202108141VA (en) Novel cd40-binding antibodies
IL279352A (en) Il-11ra antibodies
GB201905150D0 (en) Ant-ige antibodies
IL278010A (en) Galectin-10 antibodies
SG11202106171WA (en) Anti-btla antibodies
IL277030A (en) Antibodies
IL284584A (en) Anti-tigit antibodies
ZA202108836B (en) Anti-epha4 antibody
GB2581174B (en) Antibodies against hEPCR
SG11202102114UA (en) Anti-klrg1 antibodies
GB201900732D0 (en) Antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
SG11201913540VA (en) Anti-Podoplanin Antibody
IL289160A (en) Anti-angpt2 antibodies
PT4025612T (en) Anti-fucosyl-gm1 antibodies
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB201919062D0 (en) Antibody
GB201919280D0 (en) Antibodies
GB201901648D0 (en) Galectin-10 antibodies
GB201912008D0 (en) Antibody

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)